At the time of writing, Biogen Inc [BIIB] stock is trading at $123.70, up 2.77%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BIIB shares have gain 4.49% over the last week, with a monthly amount glided 5.74%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on April 28, 2025, when HSBC Securities downgraded its rating to a Hold but kept the price target unchanged to $118 for it. Previously, Argus downgraded its rating to Hold on April 04, 2025. On February 11, 2025, Bernstein initiated with a Mkt Perform rating and assigned a price target of $160 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $138 on January 02, 2025. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $164 on December 20, 2024. Stifel downgraded its rating to Hold for this stock on December 16, 2024, but kept the price target unchanged to $175.
For the past year, the stock price of Biogen Inc fluctuated between $110.04 and $238.00. Currently, Wall Street analysts expect the stock to reach $193.75 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $123.70 at the most recent close of the market. An investor can expect a potential return of 56.63% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
According to Biogen Inc [NASDAQ:BIIB], the company’s sales were 9.40B for trailing twelve months, which represents an 6.17% jump. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.09 and Total Capital is 0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 120.68 points at the first support level, and at 117.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 125.22, and for the 2nd resistance point, it is at 126.74.
Ratios To Look Out For
It is important to note that Biogen Inc [NASDAQ:BIIB] has a current ratio of 1.44. As well, the Quick Ratio is 1.01, while the Cash Ratio is 0.49. Considering the valuation of this stock, the price to sales ratio is 1.93, the price to book ratio is 1.07 and price to earnings (TTM) ratio is 12.22.
Transactions by insiders
Recent insider trading involved DORSA CAROLINE, Director, that happened on May 02 ’25 when 1235.0 shares were purchased. Director, SHERWIN STEPHEN A completed a deal on Mar 07 ’25 to sell 8760.0 shares. Meanwhile, Director STEPHEN A SHERWIN bought 8760.0 shares on Mar 07 ’25.
